Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Dr. Kim Chi, medical oncologist at the BC Cancer Agency in Vancouver, summarizes the results of the LATITUDE trial and the recently published patient-reported outcomes and health-related quality of life.

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Meet the author 17/12/2018

Quarterly Focus on Genitourinary Cancer: highlights in prostate cancer (part 2)

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Niven Mehra, MD, PhD – medical oncologist, Radboudumc, Nijmegen Andre Bergman, MD, PhD – medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Theo de Reijke, MD - urologist, Amsterdam UMC, Amsterdam Program: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE) N Engl J M, July 27, 2017 Speaker: Karim Fizazi, MD, PhD - medical oncologist, Gustave Roussy Institute, Villejuif, France Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial The Lancet, Oct 21, 2018 Speaker: Prof. Nicholas James, PhD - medical oncologist, University of Birmingham, UK

Congress news 13/12/2018

EMUC 2018: STAMPEDE trial

Prof. Nicholas James, oncologist at the University Hospitals Birmingham NHS Trust (UK), talks us through the new results of the STAMPEDE trial. Do the results of abiraterone differ in patients with high risk metastatic prostate cancer as compared to patients in the low risk category? And is there any benefit of adding radiotherapy to systemic therapy?

Congress news 13/12/2018

EMUC 2018: Highlights

Prof. Alberto Briganti, professor in the urology at the IRCCS Ospedale San Raffaele in Italy, is a member of the EMUC scientific committee on behalf of the EAU. He shares with us his personal highlights of the EMUC 2018, among which are the STAMPEDE and HORRAD trials and new radiological developments.

Congress news 13/12/2018

EMUC 2018: Delaying metastasizing with enzalutamide or apalutamide

Can metastasizing of castration resistant prostate cancer be postponed by using enzalutamide or apalutamide? Dr. Karim Fizazi, medical oncologist at the Institut Gustave Roussy in France, concludes this is the case. Furthermore, he talks about the first results of darolutamide.

Congress news 13/12/2018

EMUC 2018: HORRAD trial

In the HORRAD trial patients with prostate cancer were randomized to receive either local therapy and ADT or ADT alone. Dr. Liselotte Boevé, urologist at VU Medisch Centrum in Amsterdam, presents us the results.

Congress news 13/12/2018

EMUC 2018: Best Abstract Award

Dr. Christian Fankhauser, urologist at the UniversitätsSpital Zürich in Switzerland, has won the Best Abstract Award at the EMUC 2018. He is currently testing an algorithm designed to standardize tissue examination in order to get more uniformity in the Gleason Score assessment.

Congress news 12/12/2018

EMUC 2018: Take home messages

Dr. Laurence Albiges, medical oncologist at the Institut Gustave Roussy (France), shares with us her take home messages of EMUC 2018, several of which might have practice changing potential.